![INmune Bio, Inc. logo](/logos/INMB.webp)
INmune Bio, Inc.
NASDAQ:INMB
Overview | Financials
Company Name | INmune Bio, Inc. |
Symbol | INMB |
Currency | USD |
Price | 5.88 |
Market Cap | 116,320,512 |
Dividend Yield | 0% |
52-week-range | 5.799 - 14.74 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Raymond Joseph Tesi M.D. |
Website | https://www.inmunebio.com |
An error occurred while fetching data.
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD